Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2

Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2

Until today effective antivirals for COVID-19 treatment are not widely available. Here, Zhao et al. characterize a dual-functional cross-linking peptide, 8P9R, that can inhibit SARS-CoV-2 virus entry in vitro and suppresses viral replication in vivo in golden Syrian hamster.

Bibliographic Details
Main Authors: Hanjun Zhao, Kelvin K. W. To, Hoiyan Lam, Xinxin Zhou, Jasper Fuk-Woo Chan, Zheng Peng, Andrew C. Y. Lee, Jianpiao Cai, Wan-Mui Chan, Jonathan Daniel Ip, Chris Chung-Sing Chan, Man Lung Yeung, Anna Jinxia Zhang, Allen Wing Ho Chu, Shibo Jiang, Kwok-Yung Yuen
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-21825-w

Internet

https://doi.org/10.1038/s41467-021-21825-w

Similar Items